Pancreatic Cancer Research

ResearcherFred Hutch Cancer CenterActive in the last 2 years

Ingunn M. Stromnes

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-8120-4547; OpenAlex author ID A5014810863; NIH RePORTER profile ID 10407526. Sources: OpenAlex.

Their work

Papers
19 (first author 1, last author 9)
Trials
0
Grants
5
Labs led
1
Collaborators
17
Papers, trials and grants by year

2014: 1 paper · 2015: 1 paper · 2016: 1 paper · 2017: 1 paper, 1 grant · 2018: none · 2019: 2 papers, 1 grant · 2020: 1 paper · 2021: 1 paper · 2022: 2 papers · 2023: 3 papers · 2024: none · 2025: 2 papers, 2 grants · 2026: 4 papers, 1 grant

Papers 19

  1. Decoding spatiotemporal fibrotic and cellular immunosuppression of therapeutic T cells in live pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s44320-026-00243-4↗
  2. Treg cells promote immunotherapy-induced immune evasion by restraining CD4 T cell control of MHC-I-deficient metastatic pancreatic cancer. Last author DOI 10.1126/sciimmunol.adz4302↗
  3. Promoting tumor antigen presentation unleashes therapeutic efficacy of Tgfbr2-deficient TCR-engineered T cells in pancreatic ductal adenocarcinoma. Last author DOI 10.1136/jitc-2026-015489↗
  4. Targeting pancreatic cancer with adenoviral vectors equipped with transgenes. Co-author DOI 10.1158/1535-7163.mct-25-1231↗
  5. IL-15 complex enhances therapeutic efficacy of anti-PD-L1 in a T cell-dependent and NK cell-independent manner in a murine model of pancreatic ductal adenocarc… Last author DOI 10.1093/jimmun/vkaf314↗
  6. IL-15 Complex Enhances Agonistic Anti-CD40 + Anti-PDL1 by Correcting the T-bet to Tox Ratio in CD8+ T cells Infiltrating Pancreatic Ductal Adenocarcinoma. Last author DOI 10.1158/2326-6066.cir-24-0758↗
  7. Cxcr3 constrains pancreatic cancer dissemination through instructing T cell fate. Last author DOI 10.1007/s00262-022-03338-7↗
  8. Tumor-specific CD4 T cells instruct monocyte fate in pancreatic ductal adenocarcinoma. Last author DOI 10.1016/j.celrep.2023.112732↗
  9. IL18 at the Crossroads between Chronic Inflammation and T-cell Exhaustion in Pancreatic Cancer. Co-author DOI 10.1158/2326-6066.cir-23-0145↗
  10. Insufficiency of compound immune checkpoint blockade to overcome engineered T cell exhaustion in pancreatic cancer. Co-author DOI 10.1136/jitc-2021-003525↗
  11. Distinct myeloid antigen-presenting cells dictate differential fates of tumor-specific CD8+ T cells in pancreatic cancer. Last author DOI 10.1172/jci.insight.151593↗
  12. CD40 Agonist Overcomes T Cell Exhaustion Induced by Chronic Myeloid Cell IL-27 Production in a Pancreatic Cancer Preclinical Model. Last author DOI 10.4049/jimmunol.2000765↗
  13. Mechanisms Governing Immunotherapy Resistance in Pancreatic Ductal Adenocarcinoma. First author DOI 10.3389/fimmu.2020.613815↗
  14. Combination PD-1 and PD-L1 Blockade Promotes Durable Neoantigen-Specific T Cell-Mediated Immunity in Pancreatic Ductal Adenocarcinoma. Last author DOI 10.1016/j.celrep.2019.07.059↗
  15. Differential Effects of Depleting versus Programming Tumor-Associated Macrophages on Engineered T Cells in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/2326-6066.cir-18-0448↗
  16. T-cell Localization, Activation, and Clonal Expansion in Human Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/2326-6066.cir-16-0322↗
  17. Pancreatic Cancer: Planning Ahead for Metastatic Spread. Co-author DOI 10.1016/j.ccell.2016.05.013↗
  18. T Cells Engineered against a Native Antigen Can Surmount Immunologic and Physical Barriers to Treat Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1016/j.ccell.2015.09.022↗
  19. Targeted depletion of an MDSC subset unmasks pancreatic ductal adenocarcinoma to adaptive immunity. Co-author DOI 10.1136/gutjnl-2013-306271↗

Grants 5

  1. Elucidating properties of T cell receptors that govern pancreatic cancer immunotherapy response R01CA318724↗
  2. Mechanisms of immunotherapy response and resistance in pancreatic ductal adenocarcinoma R01CA249393↗
  3. Enhancing engineered T cell therapeutic efficacy for the treatment of pancreatic ductal adenocarcinoma R01CA255039↗
  4. Overcoming Immunotherapy Resistance in Pancreas Cancer AWARD pancan:2019-ingunn-stromnes-phd-overcoming-immunotherapy-resistance-in-p
  5. Enhancing Efficacy of Engineered T Cell Therapy for Pancreatic Cancer AWARD pancan:2017-ingunn-stromnes-enhancing-efficacy-of-engineered-t-cell-

Closest collaborators

The 17 strongest of 17 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Adam L. Burrack · 11 shared papers, 2019–2026 · strength 1.89
  2. Zoe C. Schmiechen · 8 shared papers, 2020–2026 · strength 1.60
  3. Alexander K. Tsai · 4 shared papers, 2025–2026 · strength 0.92
  4. Grant H. Hickok · 4 shared papers, 2023–2026 · strength 0.80
  5. Philip D. Greenberg · 7 shared papers, 2014–2026 · strength 0.78
  6. Sunil R. Hingorani · 6 shared papers, 2014–2026 · strength 0.66
  7. Paolo Provenzano · 2 shared papers, 2026 · strength 0.61
  8. Guhan Qian · 2 shared papers, 2026 · strength 0.61
  9. Cara-lin Lonetree · 2 shared papers, 2025–2026 · strength 0.41
  10. Kevin W. Eliceiri · 1 shared paper, 2026 · strength 0.39
  11. Brett Roach · 1 shared paper, 2026 · strength 0.33
  12. Mizuho Sato‐Dahlman · 1 shared paper, 2026 · strength 0.33
  13. Masato Yamamoto · 1 shared paper, 2026 · strength 0.33
  14. Michael T. Patterson · 2 shared papers, 2022–2023 · strength 0.30
  15. David Masopust · 1 shared paper, 2026 · strength 0.23
  16. Liang‐I Kang · 1 shared paper, 2026 · strength 0.22
  17. David G DeNardo · 1 shared paper, 2026 · strength 0.22

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.